Precision Biosciences Clinical Trial Data
Precision BioSciences announced successful Phase 1 results for PBGENE-HBV in chronic hepatitis B, showing 100% pgRNA loss to undetectable levels at the 0.4 mg/kg dose and evidence of cccDNA elimination. The company also reported that the first patient dosed with PBGENE-DMD for Duchenne muscular dystrophy completed an eight-week safety observation period with no serious adverse events, allowing the Phase 1/2 trial to proceed with additional dosing.